Lifemd, Inc. Stock Price, News & Analysis

LifeMD, Inc. (NASDAQ: LFMD/LFMDP) announced a cash dividend of $0.5546875 per share for its 8.875% Series A Cumulative Perpetual Preferred Stock. This dividend will be paid on January 17, 2023, to shareholders recorded by January 6, 2023. LifeMD is a telehealth company offering comprehensive healthcare services across all 50 states, utilizing technology to enhance accessibility and affordability of primary care, diagnostics, and treatments. This favorable announcement underscores the company's commitment to rewarding its investors.

LifeMD, Inc. (NASDAQ: LFMD) has ranked #140 on Deloitte’s Technology Fast 500™, recognizing its impressive growth in the telehealth sector. This ranking follows previous placements of #189 and #164 in 2019 and 2018, respectively. Companies are evaluated based on revenue growth from 2018 to 2021, with LifeMD demonstrating strong performance. The 2022 Fast 500 companies achieved revenue growth between 241% to 125,138%, with a median of 611%. CEO Justin Schreiber emphasized the importance of their innovative telehealth services in improving patient access and care.

LifeMD, a direct-to-patient telehealth company, announced its participation in several upcoming conferences. Key details include:

• BTIG Digital Health Forum: Nov 21, 2022, at 1:00 PM EST, focusing on Virtual Primary Care and Health Services.
• Piper Sandler 34th Annual Healthcare Conference: Nov 29-Dec 1, 2022, with one-on-one meetings available.
• RHK Capital 2022 Disruptive Growth Conference: Dec 5-6, 2022, featuring presentations and individual meetings.

Live presentation links will be accessible on the company's investor webpage.

LifeMD reported its thirteenth consecutive quarter of record revenue, achieving $31.4 million in Q3 2022, a 26% increase year-over-year. The company improved its adjusted EPS to $(0.03), marking a 91% enhancement from the previous year. The consolidated adjusted EBITDA loss was reduced to $889,000, with expectations of achieving profitability in Q4 2022. The company saw a 36% rise in telehealth active subscribers and a 57% increase in WorkSimpli revenue. Management remains focused on maximizing shareholder value amid ongoing negotiations for the divestiture of WorkSimpli.

LifeMD, Inc. (NASDAQ: LFMD) has announced it will release its financial results for Q3 2022 on November 10, 2022, after market close. The company's management will conduct a conference call at 4:30 PM ET to discuss the results and provide additional corporate updates. LifeMD specializes in direct-to-patient telehealth services across various medical fields, enhancing access to affordable healthcare through its technology platform and nationwide pharmacy network.

LifeMD, Inc. (NASDAQ: LFMD/LFMDP) announced a cash dividend of $0.5546875 per share for its 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP). This dividend will be paid on October 17, 2022, to shareholders on record as of October 7, 2022. LifeMD is recognized for its direct-to-patient telehealth services across the U.S., providing accessible healthcare through its advanced technology platform and pharmacy network.

LifeMD, Inc. (NASDAQ: LFMD) announces the appointment of Bobby Jindal, former Governor of Louisiana, to its board of directors. Jindal aims to enhance LifeMD's telehealth services and drive innovative healthcare access. With a significant background in healthcare policy and management, he brings valuable insights to the company. LifeMD seeks to leverage his expertise to expand its services and strengthen its market position. This move is expected to empower LifeMD's vision of improving healthcare accessibility through technology-driven solutions.

LifeMD, a telehealth company, has expanded its primary care platform by offering free at-home screening kits for early detection of colon and breast cancer. The Aware® Breast Self Exam pad and EZ Detect™ at-home test are designed to empower patients in proactive health management. This initiative is part of LifeMD's commitment to enhancing diagnostic capabilities and preventive care through strategic partnerships. The kits will be available free with a LifeMD membership, reinforcing the importance of early detection in successful treatment outcomes.

LifeMD (NASDAQ: LFMD) announces a strategic partnership between its allergy telehealth subsidiary, Cleared, and Allergenis, aiming to enhance food allergy management. Cleared will serve as the exclusive telehealth provider for Allergenis' breakthrough peanut allergy diagnostic blood test, which boasts a 93% accuracy rate and eliminates the need for risky oral food challenges. With an estimated 32 million Americans affected by food allergies, this collaboration seeks to address the long wait times for allergist appointments and improve access to essential allergy testing.